SBLENDORIO GLENN
SEC insider (Form 3/4/5 filer). CIK 0001277478. Director at 4D Molecular Therapeutics, Inc. (FDMT) and 2 other issuers. 6 reported Form 4/5 transactions since Sep 2024; latest on Jun 17, 2026. Located in EMERYVILLE, CA.
Companies SBLENDORIO GLENN has filed insider reports for
- 4D Molecular Therapeutics, Inc. (FDMT): Director
- AMICUS THERAPEUTICS, INC. (FOLD): Director
- Mineralys Therapeutics, Inc. (MLYS): Director
SBLENDORIO GLENN
CIK: 0001277478
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 17, 2026FDMT
4D Molecular Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
50K shares- - Apr 27, 2026FOLD
AMICUS THERAPEUTICS, INC.
DispositionDirect142.6K shares at avg. $14.50$2.1M - Feb 19, 2026MLYS
Mineralys Therapeutics, Inc.
AwardDirect6.2K shares- - Jan 5, 2026FDMT
4D Molecular Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
45K shares- - Jun 5, 2025FOLD
AMICUS THERAPEUTICS, INC.
AwardDirect20.4K shares- - Feb 13, 2025MLYS
Mineralys Therapeutics, Inc.
AwardDirectStock Option
32.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 17, 2026 |  FDMT 4D Molecular Therapeutics, Inc. | Award Stock Option (Right to Buy) | 50,000 | - | - | Direct |
| Apr 27, 2026 |  FOLD AMICUS THERAPEUTICS, INC. | Disposition | 142,564 | $14.50 | $2,067,178 | Direct |
| Feb 19, 2026 |  MLYS Mineralys Therapeutics, Inc. | Award | 6,200 | - | $0 | Direct |
| Jan 5, 2026 | FDMT 4D Molecular Therapeutics, Inc. | Award Stock Option (Right to Buy) | 45,000 | - | - | Direct |
| Jun 5, 2025 | FOLD AMICUS THERAPEUTICS, INC. | Award | 20,414 | - | - | Direct |
| Feb 13, 2025 | MLYS Mineralys Therapeutics, Inc. | Award Stock Option | 32,900 | - | - | Direct |
1-6 of 6 transactions